1. Survey summary PTCL clinical practice recommendations

2. Q1 - What is your age? # Answer % Count 1 30-39 years 3.23% 2
41.94% 13 3
50-59 years
38.71% 12 4
60-69 years
12.90% 5
70+ years
Total
100% 31

3. Q2 - How many years have you been in
practice since completing your specialty training? #
Answer %
Count 1
< 5 years
0.00% 2
5-9 years
9.68% 3
10-19 years
48.39% 15 4
20-29 years
29.03% 9 5
30+ years
12.90%
Total
100% 31

4. Q3 - Do you consider yourself#
Answer %
Count 1
A transplant physician (defined as spending >75% of your time in the care of patients undergoing autologous or allogeneic HCT)
25.81% 8 2
A hematologist, Oncologist, or hematologist-Oncologist (defined as spending >75% of your time in the care of patients in a non-transplant setting)
35.48% 11 3
A mixed practice (50% transplant and 50% non-transplant practice)
38.71% 12
Total
100% 31

5. Q4 - To the best of your knowledge, how many
autologous HCT does your center perform every year (all diseases)? #
Answer %
Count 1
< 50
9.68% 3 2
50-99
29.03% 9
16.13% 5 4
200+
35.48% 11
Total
100% 31

6. Q5 - To the best of your knowledge, how
many allogeneic HCT does your center perform every year (all diseases)? #
Answer %
Count 1
< 50
13.33% 4 2
50-99
23.33% 7 3
20.00% 6
16.67% 5
200+
26.67% 8
Total
100% 30

7. Q7 - Peripheral T-cell lymphoma, NOS
Is there a role for high-dose
chemotherapy and autologous HCT in front-line consolidation (i.e. CR1 or PR1)? #
Answer %
Count 1
Yes
96.67% 29 2 No
3.33%
Total
100% 30

8. Q8 - Peripheral T-cell lymphoma, NOS
Does the IPI-score at diagnosis influence your
decision to consider (or not) high-dose chemotherapy and autologous HCT in
front-line consolidation (i.e. CR1 or PR1)? #
Answer %
Count 1
Yes
50.00% 15 2 No
Total
100% 30

9. Q9 - Peripheral T-cell lymphoma, NOS
Does the PIT-score at diagnosis
influence your decision to consider (or not) high-dose chemotherapy and
autologous HCT in front-line consolidation (i.e. CR1 or PR1)? #
Answer %
Count 1
Yes
44.83% 13 2 No
55.17% 16
Total
100% 29

10. Q10 - Peripheral T-cell lymphoma, NOS
Does presence of bone marrow involvement with disease at diagnosis influence your choice of transplant modality? #
Answer %
Count 1
Yes, favors allogeneic HCT
46.43% 13 2
No, autologous HCT remains an acceptable modality
53.57% 15
Total
100% 28

11. Q11 - Peripheral T-cell lymphoma, NOS
Is there a role for allogeneic HCT in
front-line consolidation (i.e. CR1 or PR1)? #
Answer %
Count 1
Yes
64.00% 16 2 No
36.00% 9
Total
100% 25

12. Q12 - Peripheral T-cell lymphoma, NOS
Does the IPI-score at diagnosis influence
your decision to consider (or not) allogeneic HCT in front-line consolidation (i.e. CR1 or PR1)? #
Answer %
Count 1
Yes
25.93% 7 2 No
74.07% 20
Total
100% 27

13. Q13 - Peripheral T-cell lymphoma, NOS
Does the PIT-score at diagnosis influence
your decision to consider (or not) allogeneic HCT in front-line consolidation (i.e. CR1 or PR1)? #
Answer %
Count 1
Yes
22.22% 6 2 No
77.78% 21
Total
100% 27

14. Q14 - Peripheral T-cell lymphoma, NOS
Is there a role for high-dose chemotherapy and autologous HCT in treatment of chemosensitive relapsed disease? #
Answer %
Count 1
Yes (only if autologous HCT not done in front-line consolidation)
88.89% 24 5
Yes (even if autologous HCT done in front-line consolidation)
0.00% 2 No
11.11% 3
Total
100% 27

15. Q15 - Peripheral T-cell lymphoma, NOS
Is there a role for allogeneic HCT in
chemosensitive relapsed disease? #
Answer %
Count 1
Yes (even if autologous HCT done in front-line consolidation)
100.00% 30 2 No
0.00%
Total
100%

16. Q16 - Peripheral T-cell lymphoma, NOS
Is there a role for high-dose chemotherapy and autologous HCT in treatment of refractory disease (primary refractory or refractory relapse)? #
Answer %
Count 1
Yes
16.67% 5 2 No
83.33% 25
Total
100% 30

17. Q17 - Peripheral T-cell lymphoma, NOS
Is there a role for allogeneic HCT in treatment of refractory disease (primary refractory or refractory relapse)? #
Answer %
Count 1
Yes
74.07% 20 2 No
25.93% 7
Total
100% 27

18. Q19 - Angioimmunoblastic T-cell lymphoma
Is there a role for high-dose
chemotherapy and autologous HCT in front-line consolidation (i.e. CR1 or PR1)? #
Answer %
Count 1
Yes
88.00% 22 2 No
12.00% 3
Total
100% 25

19. Q20 – Angioimmunoblastic T-cell lymphoma
Does the IPI-score at diagnosis influence
your decision to consider (or not) high-dose chemotherapy and autologous HCT in
front-line consolidation (i.e. CR1 or PR1)? #
Answer %
Count 1
Yes
38.46% 10 2 No
61.54% 16
Total
100% 26

20. Q21 –Angioimmunoblastic T-cell lymphoma
Does presence of bone marrow involvement at diagnosis influence your choice of transplant modality? #
Answer %
Count 1
Yes, favor allogeneic HCT
41.67% 10 2
No, autologous HCT remains an acceptable modality
58.33% 14
Total
100% 24

21. Q22 - Angioimmunoblastic T-cell lymphoma
Is there a role for allogeneic HCT in
front-line consolidation (i.e. CR1 or PR1)? #
Answer %
Count 1
Yes
36.36% 8 2 No
63.64% 14
Total
100% 22

22. Q23 - Angioimmunoblastic T-cell lymphoma
Does the IPI-score at diagnosis influence
your decision to consider (or not) allogeneic HCT in front-line consolidation (i.e. CR1 or PR1)? #
Answer %
Count 1
Yes
30.43% 7 2 No
69.57% 16
Total
100% 23

23. Q24 - Angioimmunoblastic T-cell lymphoma
Is there a role for high-dose chemotherapy and autologous HCT in treatment of chemosensitive relapsed disease? #
Answer %
Count 1
Yes (only if autologous HCT not done in front-line consolidation)
84.62% 22 5
Yes (even if autologous HCT done in front-line consolidation)
3.85% 2 No
11.54% 3
Total
100% 26

24. Q25 - Angioimmunoblastic T-cell lymphoma
Is there a role for allogeneic HCT in
chemosensitive relapsed disease? #
Answer %
Count 1
Yes (even if autologous HCT done in front-line consolidation)
96.30% 26 2 No
3.70%
Total
100% 27

25. Q26 - Angioimmunoblastic T-cell lymphoma
Is there a role for high-dose chemotherapy and autologous HCT in treatment of refractory disease (primary refractory or refractory relapse)? #
Answer %
Count 1
Yes
15.38% 4 2 No
84.62% 22
Total
100% 26

26. Q27 - Angioimmunoblastic T-cell lymphoma
Is there a role for allogeneic HCT in treatment of refractory disease (primary refractory or refractory relapse)? #
Answer %
Count 1
Yes
79.17% 19 2 No
20.83% 5
Total
100% 24

27. Q29 -Anaplastic large-cell lymphoma, ALK+
Is there a role for high-dose
chemotherapy and autologous HCT in front-line consolidation (i.e. CR1 or PR1)? #
Answer %
Count 1
Yes
24.00% 6 2 No
76.00% 19
Total
100% 25

28. Q30 - Anaplastic large-cell lymphoma, ALK+
Does the IPI-score at diagnosis influence
your decision to consider (or not) high-dose chemotherapy and autologous HCT in
front-line consolidation (i.e. CR1 or PR1)? #
Answer %
Count 1
Yes
30.43% 7 2 No
69.57% 16
Total
100% 23

29. Q31 - Anaplastic large-cell lymphoma, ALK+
Does presence of bone marrow involvement at diagnosis influence your choice of transplant modality? #
Answer %
Count 1
Yes, favor allogeneic HCT
25.00% 4 2
No, autologous HCT remains an acceptable modality
75.00% 12
Total
100% 16

30. Q32 - Anaplastic large-cell lymphoma, ALK+
Is there a role for allogeneic HCT in
front-line consolidation (i.e. CR1 or PR1)? #
Answer %
Count 1
Yes
4.00% 2 No
96.00% 24
Total
100% 25

31. Q33 - Anaplastic large-cell lymphoma, ALK+
Does the IPI-score at diagnosis influence
your decision to consider (or not) allogeneic HCT in front-line consolidation (i.e. CR1 or PR1)? #
Answer %
Count 1
Yes
4.55% 2 No
95.45% 21
Total
100% 22

32. Q34 - Anaplastic large-cell lymphoma, ALK+
Is there a role for high-dose chemotherapy and autologous HCT in treatment of chemosensitive relapsed disease? #
Answer %
Count 1
Yes (only if autologous HCT not done in front-line consolidation)
100.00% 26 5
Yes (even if autologous HCT done in front-line consolidation)
0.00% 2 No
Total
100%

33. Q35 - Anaplastic large-cell lymphoma, ALK+
Is there a role for allogeneic HCT in
chemosensitive relapsed disease? #
Answer %
Count 1
Yes (even if autologous done in front-line consolidation)
83.33% 20 2 No
16.67% 4
Total
100% 24

34. Q36 - Anaplastic large-cell lymphoma, ALK+
Is there a role for high-dose chemotherapy and autologous HCT in treatment of refractory disease (primary refractory or refractory relapse)? #
Answer %
Count 1
Yes
20.83% 5 2 No
79.17% 19
Total
100% 24

35. Q37 - Anaplastic large-cell lymphoma, ALK+
Is there a role for allogeneic HCT in treatment of refractory disease (primary refractory or refractory relapse)? #
Answer %
Count 1
Yes
70.83% 17 2 No
29.17% 7
Total
100% 24

36. Q39 - Anaplastic large-cell lymphoma, ALK- (negative)
Is there a role for high-dose
chemotherapy and autologous HCT in front-line consolidation (i.e. CR1 or PR1)? #
Answer %
Count 1
Yes
92.00% 23 2 No
8.00%
Total
100% 25

37. Q41 - Anaplastic large-cell lymphoma, ALK- (negative)
Does presence of bone marrow involvement at diagnosis influence your choice of transplant modality? #
Answer %
Count 1
Yes, favor allogeneic HCT
33.33% 8 2
No, autologous HCT remains an acceptable modality
66.67% 16
Total
100% 24

38. Q40 - Anaplastic large-cell lymphoma, ALK- (negative)
Does the IPI-score at diagnosis influence
your decision to consider (or not) high-dose chemotherapy and autologous HCT in
front-line consolidation (i.e. CR1 or PR1)? #
Answer %
Count 1
Yes
38.46% 10 2 No
61.54% 16
Total
100% 26

39. Q42 - Anaplastic large-cell lymphoma, ALK- (negative)
Is there a role for allogeneic HCT in
front-line consolidation (i.e. CR1 or PR1)? #
Answer %
Count 1
Yes
29.17% 7 2 No
70.83% 17
Total
100% 24

40. Q43 - Anaplastic large-cell lymphoma, ALK- (negative)
Does the IPI-score at diagnosis influence
your decision to consider (or not) allogeneic HCT in front-line consolidation (i.e. CR1 or PR1)? #
Answer %
Count 1
Yes
29.17% 7 2 No
70.83% 17
Total
100% 24

41. Q44 - Anaplastic large-cell lymphoma, ALK- (negative)
Is there a role for high-dose chemotherapy and autologous HCT in treatment of chemosensitive relapsed disease? #
Answer %
Count 1
Yes (only if autologous HCT not done in front-line consolidation)
88.89% 24 5
Yes (even if autologous HCT done in front-line consolidation)
0.00% 2 No
11.11% 3
Total
100% 27

42. Q45 - Anaplastic large-cell lymphoma, ALK- (negative)
Is there a role for allogeneic HCT in
chemosensitive relapsed disease? #
Answer %
Count 1
Yes (even if autologous HCT done in front-line consolidation)
96.30% 26 2 No
3.70%
Total
100% 27

43. Q46 -Anaplastic large-cell lymphoma, ALK- (negative)
Is there a role for high-dose chemotherapy and autologous HCT in treatment of refractory disease (primary refractory or refractory relapse)? #
Answer %
Count 1
Yes
23.08% 6 2 No
76.92% 20
Total
100% 26

44. Q47 -Anaplastic large-cell lymphoma, ALK- (negative)
Is there a role for allogeneic HCT in treatment of refractory disease (primary refractory or refractory relapse)? #
Answer %
Count 1
Yes
82.61% 19 2 No
17.39% 4
Total
100% 23

45. Q49 -Extranodal NK/T-cell lymphoma nasal type
Localized
Front-line:
Is there a role for high-dose
chemotherapy and autologous HCT in front-line consolidation (i.e. CR1 or PR1)? #
Answer %
Count 1
Yes
24.00% 6 2 No
76.00% 19
Total
100% 25

46. Q50 - Extranodal NK/T-cell lymphoma nasal type
Localized
Front-line:
Is there a role for allogeneic HCT in
front-line consolidation (i.e. CR1 or PR1)? #
Answer %
Count 1
Yes
17.39% 4 2 No
82.61% 19
Total
100% 23

47. Q51 - Extranodal NK/T-cell lymphoma nasal type
Localized
Is there a role for high-dose chemotherapy and autologous HCT in treatment of chemosensitive relapsed disease? #
Answer %
Count 1
Yes
82.61% 19 2 No
17.39% 4
Total
100% 23

48. Q52 -Extranodal NK/T-cell lymphoma nasal type
Localized
Is there a role for allogeneic HCT in
chemosensitive relapsed disease? #
Answer %
Count 1
Yes
91.67% 22 2 No
8.33%
Total
100% 24

49. Q53 - Extranodal NK/T-cell lymphoma nasal type
Localized
Is there a role for high-dose chemotherapy and autologous HCT in treatment of Chemoresistant/refractory disease? #
Answer %
Count 1
Yes
25.00% 6 2 No
75.00% 18
Total
100% 24

50. Q54 - Extranodal NK/T-cell lymphoma nasal type
Localized
Is there a role for allogeneic HCT in treatment of Chemoresistant/refractory disease? #
Answer %
Count 1
Yes
81.82% 18 2 No
18.18% 4
Total
100% 22

51. Q56 –Extranodal NK/T-cell lymphoma nasal type
Disseminated
Front-line:
Is there a role for high-dose chemotherapy and autologous HCT in front-line consolidation in disseminated disease (i.e. CR1 or PR1)? #
Answer %
Count 1
Yes
79.17% 19 2 No
20.83% 5
Total
100% 24

52. Q57 - Extranodal NK/T-cell lymphoma nasal type
Disseminated
Front-line:
Is there a role for allogeneic HCT in front-line consolidation in disseminated disease (i.e. CR1 or PR1)? #
Answer %
Count 1
Yes
86.96% 20 2 No
13.04% 3
Total
100% 23

53. Q58 - Extranodal NK/T-cell lymphoma nasal type
Disseminated
Is there a role for high-dose chemotherapy and autologous HCT in treatment of disseminated chemosensitive relapsed disease? #
Answer %
Count 1
Yes
70.83% 17 2 No
29.17% 7
Total
100% 24

54. Q59 - Extranodal NK/T-cell lymphoma nasal type
Disseminated
Is there a role for allogeneic HCT in treatment of disseminated chemosensitive relapsed disease? #
Answer %
Count 1
Yes
100.00% 24 2 No
0.00%
Total
100%

55. Q60 - Extranodal NK/T-cell lymphoma nasal type
Disseminated
Is there a role for high-dose chemotherapy and autologous HCT in treatment of Chemoresistant/refractory disease? #
Answer %
Count 1
Yes
20.83% 5 2 No
79.17% 19
Total
100% 24

56. Q61 -Extranodal NK/T-cell lymphoma nasal type
Disseminated
Is there a role for allogeneic HCT in treatment of Chemoresistant/refractory disease? #
Answer %
Count 1
Yes
72.73% 16 2 No
27.27% 6
Total
100% 22

57. Q63 – Adult T-cell Leukemia/Lymphoma
Acute:
Front-line:
Is there a role for high-dose
chemotherapy and autologous HCT in front-line consolidation (i.e. CR1 or PR1)? #
Answer %
Count 1
Yes
23.81% 5 2 No
76.19% 16
Total
100% 21

58. Q64 - Adult T-cell Leukemia/Lymphoma
Acute:
Front-line:
Is there a role for allogeneic HCT in
front-line consolidation (i.e. CR1 or PR1)? #
Answer %
Count 1
Yes
90.91% 20 2 No
9.09%
Total
100% 22

59. Q65 – Adult T-cell Leukemia/Lymphoma
Acute:
Is there a role for high-dose chemotherapy and autologous HCT in treatment of relapsed responsive disease? #
Answer %
Count 1
Yes
13.64% 3 2 No
86.36% 19
Total
100% 22

60. Acute: Q66 - Adult T-cell Leukemia/Lymphoma
Is there a role for allogeneic HCT in relapsed responsive disease? #
Answer %
Count 1
Yes
100.00% 21 2 No
0.00%
Total
100%

61. Q67 - Adult T-cell Leukemia/Lymphoma
Acute:
Is there a role for high-dose chemotherapy and autologous HCT in treatment of relapsed resistant disease/refractory disease? #
Answer %
Count 1
Yes
8.70% 2 No
91.30% 21
Total
100% 23

62. Q68 - Adult T-cell Leukemia/Lymphoma
Acute:
Is there a role for allogeneic HCT in treatment of relapsed resistant disease/refractory disease? #
Answer %
Count 1
Yes
73.68% 14 2 No
26.32% 5
Total
100% 19

63. Q70 - Adult T-cell Leukemia/Lymphoma
Lymphoma type:
Front-line:
Is there a role for high-dose
chemotherapy and autologous HCT in front-line consolidation (i.e. CR1 or PR1)? #
Answer %
Count 1
Yes
31.25% 5 2 No
68.75% 11
Total
100% 16

64. Q71 - Adult T-cell Leukemia/Lymphoma
Lymphoma type:
Front-line:
Is there a role for allogeneic HCT in
front-line consolidation (i.e. CR1 or PR1)? #
Answer %
Count 1
Yes
70.00% 14 2 No
30.00% 6
Total
100% 20

65. Q72 -Adult T-cell Leukemia/Lymphoma
Lymphoma type:
Is there a role for high-dose chemotherapy and autologous HCT in treatment of relapsed sensitive disease? #
Answer %
Count 1
Yes
30.00% 6 2 No
70.00% 14
Total
100% 20

66. Lymphoma type: Q73 - Adult T-cell Leukemia/Lymphoma
Is there a role for allogeneic HCT in relapsed sensitive disease? #
Answer %
Count 1
Yes
100.00% 21 2 No
0.00%
Total
100%

67. Q74 - Adult T-cell Leukemia/Lymphoma
Lymphoma type:
Is there a role for high-dose chemotherapy and autologous HCT in treatment of relapsed resistant disease/refractory disease? #
Answer %
Count 1
Yes
4.55% 2 No
95.45% 21
Total
100% 22

68. Q75 -Adult T-cell Leukemia/Lymphoma
Lymphoma type:
Is there a role for allogeneic HCT in treatment of relapsed resistant disease/refractory disease? #
Answer %
Count 1
Yes
83.33% 15 2 No
16.67% 3
Total
100% 18

69. Q77 - Adult T-cell Leukemia/Lymphoma
Smoldering/chronic:
Front-line
Is there a role for high-dose
chemotherapy and autologous HCT in front-line consolidation (i.e. CR1 or PR1)? #
Answer %
Count 1
Yes
10.53% 2 No
89.47% 17
Total
100% 19

70. Q78 - Adult T-cell Leukemia/Lymphoma
Smoldering/chronic:
Front-line
Is there a role for allogeneic HCT in
front-line consolidation (i.e. CR1 or PR1)? #
Answer %
Count 1
Yes
20.00% 4 2 No
80.00% 16
Total
100% 20

71. Q79 -Adult T-cell Leukemia/Lymphoma
Smoldering/chronic:
Is there a role for high-dose chemotherapy and autologous HCT in treatment of relapse sensitive disease? #
Answer %
Count 1
Yes
27.78% 5 2 No
72.22% 13
Total
100% 18

72. Smoldering/chronic: Q80 -Adult T-cell Leukemia/Lymphoma
Is there a role for allogeneic HCT in relapsed sensitive disease? #
Answer %
Count 1
Yes
78.95% 15 2 No
21.05% 4
Total
100% 19

73. Q81 - Adult T-cell Leukemia/Lymphoma
Smoldering/chronic:
Is there a role for high-dose chemotherapy and autologous HCT in treatment of relapse resistant/refractory disease? #
Answer %
Count 1
Yes
10.00% 2 No
90.00% 18
Total
100% 20

74. Q82 -Adult T-cell Leukemia/Lymphoma
Smoldering/chronic:
Is there a role for allogeneic HCT in relapse resistant/refractory disease? #
Answer %
Count 1
Yes
76.47% 13 2 No
23.53% 4
Total
100% 17

75. Q84 -Mycosis Fungoides/Sezary syndrome
Early stage (IA, IB, IIA) patch and/or plaque phase:
Front-line:
Is there a role for high-dose
chemotherapy and autologous HCT as part of front-line therapy? #
Answer %
Count 1
Yes
0.00% 2 No
100.00% 24
Total
100%

76. Early stage (IA, IB, IIA) patch and/or plaque phase: Front-line:
Q85 -Mycosis Fungoides/Sezary syndrome
Early stage (IA, IB, IIA) patch and/or plaque phase:
Front-line:
Is there a role for allogeneic HCT as part of front-line therapy? #
Answer %
Count 1
Yes
4.17% 2 No
95.83% 23
Total
100% 24

77. Q86 -Mycosis Fungoides/Sezary syndrome
Early stage (IA, IB, IIA) patch and/or plaque phase:
Is there a role for high-dose chemotherapy and autologous HCT in treatment of relapsed responsive disease? #
Answer %
Count 1
Yes
4.35% 2 No
95.65% 22
Total
100% 23

78. Early stage (IA, IB, IIA) patch and/or plaque phase:
Q87 -Mycosis Fungoides/Sezary syndrome
Early stage (IA, IB, IIA) patch and/or plaque phase:
Is there a role for allogeneic HCT in relapsed responsive disease? #
Answer %
Count 1
Yes
52.17% 12 2 No
47.83% 11
Total
100% 23

79. Q88 - Mycosis Fungoides/Sezary syndrome
Early stage (IA, IB, IIA) patch and/or plaque phase:
Is there a role for high-dose chemotherapy and autologous HCT in treatment of relapsed-resistant disease? #
Answer %
Count 1
Yes
9.09% 2 No
90.91% 20
Total
100% 22

80. Early stage (IA, IB, IIA) patch and/or plaque phase:
Q89 -Mycosis Fungoides/Sezary syndrome
Early stage (IA, IB, IIA) patch and/or plaque phase:
Is there a role for allogeneic HCT in relapsed-resistant disease? #
Answer %
Count 1
Yes
54.55% 12 2 No
45.45% 10
Total
100% 22

81. Q91 -Advanced stage disease (IIB-IVB): tumor phase, Sezary syndrome, and/or nodal/extracutaneous disease
Front-line therapy:
Is there a role for high-dose
chemotherapy and autologous HCT as part of front-line therapy? #
Answer %
Count 1
Yes
13.64% 3 2 No
86.36% 19
Total
100% 22

82. Q92 --Advanced stage disease (IIB-IVB): tumor phase, Sezary syndrome, and/or nodal/extracutaneous disease
Front-line therapy:
Is there a role for allogeneic HCT as part of front-line therapy? #
Answer %
Count 1
Yes
50.00% 11 2 No
Total
100% 22

83. Q93 - -Advanced stage disease (IIB-IVB): tumor phase, Sezary syndrome, and/or nodal/extracutaneous disease
Is there a role for high-dose chemotherapy and autologous HCT in treatment of relapsed/responsive disease? #
Answer %
Count 1
Yes
20.00% 4 2 No
80.00% 16
Total
100% 20

84. Is there a role for allogeneic HCT in relapsed/responsive disease?
Q94 --Advanced stage disease (IIB-IVB): tumor phase, Sezary syndrome, and/or nodal/extracutaneous disease
Is there a role for allogeneic HCT in relapsed/responsive disease? #
Answer %
Count 1
Yes
100.00% 22 2 No
0.00%
Total
100%

85. Q95 --Advanced stage disease (IIB-IVB): tumor phase, Sezary syndrome, and/or nodal/extracutaneous disease
Is there a role for high-dose chemotherapy and autologous HCT in treatment of relapsed-resistant disease? #
Answer %
Count 1
Yes
4.55% 2 No
95.45% 21
Total
100% 22

86. Is there a role for allogeneic HCT in relapsed-resistant disease?
Q96 - -Advanced stage disease (IIB-IVB): tumor phase, Sezary syndrome, and/or nodal/extracutaneous disease
Is there a role for allogeneic HCT in relapsed-resistant disease? #
Answer %
Count 1
Yes
85.71% 18 2 No
14.29% 3
Total
100% 21

87. Q98 -Subcutaneous panniculitis-like T cell lymphoma
Front-line:
Is there a role for high-dose
chemotherapy and autologous HCT as part of front-line consolidation? #
Answer %
Count 1
Yes
31.58% 6 2 No
68.42% 13
Total
100% 19

88. Q99 -Subcutaneous panniculitis-like T cell lymphoma
Front-line:
Is there a role for allogeneic HCT as part of front-line consolidation? #
Answer %
Count 1
Yes
31.58% 6 2 No
68.42% 13
Total
100% 19

89. Q100 -Subcutaneous panniculitis-like T cell lymphoma
Is there a role for high-dose chemotherapy and autologous HCT in treatment of chemosensitive relapsed disease? #
Answer %
Count 1
Yes
55.56% 10 2 No
44.44% 8
Total
100% 18

90. Q101 -Subcutaneous panniculitis-like T cell lymphoma
Is there a role for allogeneic HCT in chemosensitive relapsed disease? #
Answer %
Count 1
Yes
84.21% 16 2 No
15.79% 3
Total
100% 19

91. Q102 -Subcutaneous panniculitis-like T cell lymphoma
Is there a role for high-dose chemotherapy and autologous HCT in treatment of chemoresistant/refractory disease? #
Answer %
Count 1
Yes
5.26% 2 No
94.74% 18
Total
100% 19

92. Q103 -Subcutaneous panniculitis-like T cell lymphoma
Is there a role for allogeneic HCT in chemoresistant/refractory disease? #
Answer %
Count 1
Yes
72.22% 13 2 No
27.78% 5
Total
100% 18

93. Q105 -Enteropathy associated T-cell lymphoma
Front-line:
Is there a role for high-dose
chemotherapy and autologous HCT in front-line consolidation? #
Answer %
Count 1
Yes
73.91% 17 2 No
26.09% 6
Total
100% 23

94. Front-line: Q106 -Enteropathy associated T-cell lymphoma
Is there a role for allogeneic HCT in front-line consolidation? #
Answer %
Count 1
Yes
11.76% 2 No
88.24% 15
Total
100% 17

95. Q107 -Enteropathy associated T-cell lymphoma
Is there a role for high-dose chemotherapy and autologous HCT in treatment of relapsed disease? #
Answer %
Count 1
Yes
66.67% 14 2 No
33.33% 7
Total
100% 21

96. Q108 -Enteropathy associated T-cell lymphoma
Is there a role for allogeneic HCT in relapsed disease? #
Answer %
Count 1
Yes
94.44% 17 2 No
5.56%
Total
100% 18

97. Q110 -Hepatosplenic Gamma Delta T-cell lymphoma
Front-line:
Is there a role for high-dose
chemotherapy and autologous HCT in front-line consolidation? #
Answer %
Count 1
Yes
55.00% 11 2 No
45.00% 9
Total
100% 20

98. Front-line: Q111 - Hepatosplenic Gamma Delta T-cell lymphoma
Is there a role for allogeneic HCT in front-line consolidation? #
Answer %
Count 1
Yes
93.75% 15 2 No
6.25%
Total
100% 16

99. Q112 - Hepatosplenic Gamma Delta T-cell lymphoma
Is there a role for high-dose chemotherapy and autologous HCT in treatment of relapsed disease? #
Answer %
Count 1
Yes
40.00% 8 2 No
60.00% 12
Total
100% 20

100. Q113 - Hepatosplenic Gamma Delta T-cell lymphoma
Is there a role for allogeneic HCT in relapsed disease? #
Answer %
Count 1
Yes
100.00% 21 2 No
0.00%
Total
100%

101. Q115 - When performing an autologous HCT,
what is your preferred conditioning regimen #
Answer %
Count 1
BEAM/BEAC
95.00% 19 2
TBI-based
0.00% 3
CBV
5.00% 4
Thiotepa-based 5
Other
Total
100% 20

102. Q116 - Is there a role for post-autologous
maintenance therapy in mature T/NK-cell lymphomas? #
Answer %
Count 1
Yes
5.00% 2 No
95.00% 19
Total
100% 20

103. Q117 - IF yes, please specify histology type and regimen?
in CD30+ expressing lymphomas

104. Q118 - When performing an allogeneic HCT, what is your
preferred regimen intensity? #
Answer %
Count 1
Myeloablative
21.05% 4 2
Reduced intensity/non-myeloablative
78.95% 15
Total
100% 19

105. Q119 - Which regimen, why, and is there a specific disease histology
FluMel or FluCyTBI. Reserve myeloablative for young patients with high risk disease
intensity depends on co-morbidities and age of patient. Cy/TBI or Bu/Cy regimen.
Adult T-cell LL- leukemia- ablative regimen preferred for eligible patients
targeted busulfan/fludara
Fludarabine/melphalan,
Flu/Cy + ldTBI
Different but for NHL Flu/Mel
Flu-Bu2; moderate intensity (get some cytoreduction) but lower TRM than myeloablative
many RIC regimens; avoid myeloablative in lymhomas
FLU-BU (FB4), better disease control. All histologies
Fludarabine plus 6.4mg/kg IV busulfan (total dose) used for nearly all T-cell lymphomas

106. Q119 - Which regimen, why, and is there a specific disease histology
No strong preference, age related
Flu-Mel, center policy, myeloablative if young patient and first SCT. No difference depending on histology
Sequential conditioning
Fludarabin, Busulfan, Cyclophosphamid; no specific disease histology
Flu-Bu-ATG

107. Q120 - What is your preferred cell source
when performing an allogeneic HCT in mature T/NK-cell lymphomas? #
Answer %
Count 1
PBSC
94.74% 18 2 BM
5.26%
Total
100% 19